USA - NASDAQ:ATAI - NL0015000DX5 - Common Stock
The current stock price of ATAI is 5.23 USD. In the past month the price increased by 14.44%. In the past year, price increased by 350.86%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 52 | 794.90B | ||
JNJ | JOHNSON & JOHNSON | 18.86 | 454.31B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 15.21 | 264.96B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.21 | 264.50B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.96 | 256.29B | ||
MRK | MERCK & CO. INC. | 11.58 | 222.78B | ||
PFE | PFIZER INC | 8.07 | 155.61B | ||
SNY | SANOFI-ADR | 11.41 | 124.05B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.75 | 92.51B | ||
GSK | GSK PLC-SPON ADR | 9.61 | 87.24B | ||
ZTS | ZOETIS INC | 23.54 | 64.89B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.34 | 46.11B |
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
ATAI LIFE SCIENCES NV
Prof. J.H.Bavincklaan 7
Amstelveen NOORD-HOLLAND 100022 NL
CEO: Florian Brand
Employees: 54
Phone: 31207932536
The current stock price of ATAI is 5.23 USD. The price increased by 1.75% in the last trading session.
The exchange symbol of ATAI LIFE SCIENCES NV is ATAI and it is listed on the Nasdaq exchange.
ATAI stock is listed on the Nasdaq exchange.
15 analysts have analysed ATAI and the average price target is 11.51 USD. This implies a price increase of 120.1% is expected in the next year compared to the current price of 5.23. Check the ATAI LIFE SCIENCES NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ATAI LIFE SCIENCES NV (ATAI) has a market capitalization of 1.12B USD. This makes ATAI a Small Cap stock.
ATAI LIFE SCIENCES NV (ATAI) currently has 54 employees.
ATAI LIFE SCIENCES NV (ATAI) has a support level at 4.56. Check the full technical report for a detailed analysis of ATAI support and resistance levels.
The Revenue of ATAI LIFE SCIENCES NV (ATAI) is expected to grow by 339.85% in the next year. Check the estimates tab for more information on the ATAI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ATAI does not pay a dividend.
ATAI LIFE SCIENCES NV (ATAI) will report earnings on 2025-11-11, before the market open.
ATAI LIFE SCIENCES NV (ATAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
The outstanding short interest for ATAI LIFE SCIENCES NV (ATAI) is 9.12% of its float. Check the ownership tab for more information on the ATAI short interest.
ChartMill assigns a technical rating of 10 / 10 to ATAI. When comparing the yearly performance of all stocks, ATAI is one of the better performing stocks in the market, outperforming 98.63% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ATAI. No worries on liquidiy or solvency for ATAI as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ATAI reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -72.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -78.89% | ||
ROE | -103.85% | ||
Debt/Equity | 0 |
15 analysts have analysed ATAI and the average price target is 11.51 USD. This implies a price increase of 120.1% is expected in the next year compared to the current price of 5.23.
For the next year, analysts expect an EPS growth of 46.46% and a revenue growth 339.85% for ATAI